GLP-1 overhang crushed Stevanato's valuation
The guest argued the market's reaction to GLP-1 drug capacity concerns has been excessive, creating a potential opportunity as the stock price decline far outweighs the plausible revenue impact.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.